O‐linked β‐N‐acetylglucosamine (O‐ GlcNAc ) modification: Emerging pathogenesis and a therapeutic target of diabetic nephropathy
Diabetic Medicine · 2025-02 · 42 (2)
DOI: 10.1111/dme.15436 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetic Medicine, online erschienen am 16.09.2024. Verfasst von Bingxue Qi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Precision Molecular Medicine Center, Jilin Province People's Hospital, Changchun, China. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Acetylglucosamine, Protein Processing, Post-Translational. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation, Natural Science Foundation of Jilin Province, Jilin Province Outstanding Youth Foundation.
Abstract (Originalsprache)
Aims
O‐Linked β‐N‐acetylglucosamine (O‐GlcNAc) modification, a unique post‐translational modification of proteins, is elevated in diabetic nephropathy. This review aims to summarize the current knowledge on the mechanisms by which O‐GlcNAcylation of proteins contributes to the pathogenesis and progression of diabetic nephropathy, as well as the therapeutic potential of targeting O‐GlcNAc modification for its treatment.
Methods
Current evidence in the literature was reviewed and synthesized in a narrative review.
Results
Hyperglycemia increases glucose flux into the hexosamine biosynthesis pathway, which activates glucosamino‐fructose aminotransferase expression and activity, leading to the production of O‐GlcNAcylation substrate UDP‐GlcNAc and an increase in protein O‐GlcNAcylation in kidney cells. Protein O‐GlcNAcylation regulates the function of kidney cells including mesangial cells, podocytes, and proximal tubular cells, and promotes renal interstitial fibrosis, resulting in kidney damage. Current treatments for diabetic nephropathy, such as sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors and renin–angiotensin–aldosterone system (RAAS) inhibitors, delay disease progression, and suppress protein O‐GlcNAcylation.
Conclusions
Increased protein O‐GlcNAcylation mediates renal cell damage and promotes renal interstitial fibrosis, leading to diabetic nephropathy. Although the full significance of inhibition of O‐GlcNAcylation is not yet understood, it may represent a novel target for treating diabetic nephropathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Precision Molecular Medicine Center, Jilin Province People's Hospital, Changchun, China.
- Clinical Medicine College, Changchun University of Chinese Medicine, Changchun, China.
- Division of Cellular and Systems Medicine, School of Medicine, University of Dundee, Dundee, UK.
ORCID-Profile: Li Kang
Förderung
- British Heart Foundation
- Natural Science Foundation of Jilin Province
- Jilin Province Outstanding Youth Foundation
- Diabetes UK
Zitieren
APA
Qi, B., Chen, Y., Chai, S., Lu, X., & Kang, L. (2025). O‐linked β‐N‐acetylglucosamine (O‐ GlcNAc ) modification: Emerging pathogenesis and a therapeutic target of diabetic nephropathy. Diabetic Medicine, 42(2). https://doi.org/10.1111/dme.15436
Vancouver
Qi B, Chen Y, Chai S, Lu X, Kang L. O‐linked β‐N‐acetylglucosamine (O‐ GlcNAc ) modification: Emerging pathogenesis and a therapeutic target of diabetic nephropathy. Diabetic Medicine. 2025;42(2). doi:10.1111/dme.15436
BibTeX
@article{Qi2025,
author = {Qi, Bingxue and Chen, Yang and Chai, Siyang and Lu, Xiaodan and Kang, Li},
title = {O‐linked β‐N‐acetylglucosamine (O‐ GlcNAc ) modification: Emerging pathogenesis and a therapeutic target of diabetic nephropathy},
journal = {Diabetic Medicine},
year = {2025},
volume = {42},
number = {2},
doi = {10.1111/dme.15436}
}
EUVIMED